Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Latest Press Releases

Latest Press Releases

Treating COVID-19 second wave in South Africa Photograph by Chris Allan
Press release
Press release |
21 July 2021
COVID-19
South Africa

COVID-19 vaccines: Pfizer-BioNTech and Biovac “fill and finish” deal is step in right direction but much more needed to support vaccine independence in Africa

3 min
MSF treats patients with a liposomal Amphotericin B, sold by Gilead under the brand name AmBisome. Photograph by Misha Friedman
Press release
Press release |
21 July 2021
HIV/AIDS

Breakthrough in treatment of HIV-related cryptococcal meningitis gives Gilead another opportunity to fulfil its promise to scale up access to lifesaving drug

5 min
Banner deployed by MSF in front of the World Trade Organization (WTO) in Geneva calling on certain governments to stop blocking the landmark waiver proposal on intellectual property (IP) during the pandemic.
Press release
Press release |
14 July 2021
COVID-19

As Chancellor Merkel visits US, MSF urges Germany to stop blockade on pandemic ‘TRIPS waiver’

COVID-19 response in Yaoundé, Cameroon. Round of medical staff in the Covid-19 patients ward. Photograph by Vanessa Fodjo
Press release
Press release |
09 July 2021
COVID-19

MSF response to Roche’s statement on access to tocilizumab

2 min
The MSF mobile clinic team visited post-discharge cases and patients in isolation in their home. Photograph by Mariana Abdalla
Press release
Press release |
06 July 2021
COVID-19

Tocilizumab, second drug ever recommended by WHO for COVID-19, will remain unaffordable and inaccessible for most of the world

5 min
MSF teams providing care to COVID patients in Antonio Lorena hospital, Cusco, Peru. Photograph by Clément Locquet
Press release
Press release |
29 June 2021
COVID-19
European Union

Disingenuous EU initiative attempts to derail negotiations on TRIPS Waiver of COVID-19 monopolies

3 min
COVID-19 vaccines Photograph by Albert Masias
Press release
Press release |
22 June 2021
COVID-19

Ahead of Gavi’s board meeting, MSF urges critical look at COVAX shortcomings

4 min
"" Photograph by Mariana Abdalla
Press release
Press release |
21 June 2021
COVID-19

MSF calls on BioNTech to immediately share COVID-19 vaccine technology and recipe

4 min
  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury